These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 22071230

  • 1. Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Mathew R, Pearce E, Sivaprasad S.
    Am J Ophthalmol; 2012 Mar; 153(3):490-496.e1. PubMed ID: 22071230
    [Abstract] [Full Text] [Related]

  • 2. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ, Kim CG, Yoo SJ, Cho SW, Lee DW, Kim JW, Lee JH.
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R, Richardson M, Sivaprasad S.
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [Abstract] [Full Text] [Related]

  • 4. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM, Chen E, Mariani A, Major JC, SAVE Study Group.
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M, Iida T, Kano M.
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results.
    Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M.
    Retina; 2010 Jul; 30(7):1017-24. PubMed ID: 20224469
    [Abstract] [Full Text] [Related]

  • 8. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [Abstract] [Full Text] [Related]

  • 9. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS, Cho HJ, Cho SW, Kim CG, Kim JW.
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [Abstract] [Full Text] [Related]

  • 11. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
    Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV.
    Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
    [Abstract] [Full Text] [Related]

  • 12. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA, Saroj N, Shapiro H, Freund KB.
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [Abstract] [Full Text] [Related]

  • 13. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings.
    Cohen SY, Oubraham H, Uzzan J, Dubois L, Tadayoni R.
    Retina; 2012 Sep; 32(8):1480-5. PubMed ID: 22258164
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
    Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS.
    Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
    Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group.
    Ophthalmology; 2011 Apr; 118(4):663-71. PubMed ID: 21459217
    [Abstract] [Full Text] [Related]

  • 17. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB, Lund-Andersen H, Sander B, Larsen M.
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS, Daftari I, Phillips T, Morse LS.
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [Abstract] [Full Text] [Related]

  • 20. Association between foveal microstructure and visual outcome in age-related macular degeneration.
    Shin HJ, Chung H, Kim HC.
    Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.